Improving the toxicity profile of chemotherapy for advanced ovarian cancer: A potential role for CT-2103

Journal of Experimental Therapeutics and Oncology

Volumn 4, Issue 2, 2004, Pages 131-136

  Markman, Maurie ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CT 2103; Drug therapy; Ovarian neoplasms; Taxane

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GLUTAMIC ACID; PACLITAXEL; PACLITAXEL POLIGLUMEX; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SOLUBILITY; HAIR LOSS; HUMAN; HYPERSENSITIVITY REACTION; MAXIMUM TOLERATED DOSE; MOUSE; MULTIDRUG RESISTANCE; MYALGIA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; NUDE MOUSE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; TUMOR XENOGRAFT; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; POLYGLUTAMIC ACID; SURVIVAL ANALYSIS; TAXOIDS;

EID: 4043133090     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993.
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996.
3. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000.
4. Neijt JP, Engelholm SA, Tuxen MK, et al: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084-3092, 2000.
5. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003.
6. du Bois A, Luck H-J, Meier W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1330, 2003.
7. Markman M, Bookman MA: Second-line treatment of ovarian cancer. The Oncologist 5:26-35, 2000.
8. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992.
9. Swenerton K, Jeffrey J, Stuart G, et al: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718-726, 1992.
10. Connelly E, Markman M, Kennedy A, et al: Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity. Gynecol Oncol 62:166-168, 1996.
11. Vasey P; on behalf of the Scottish Gynaecologic Cancer Trials Group: Preliminary results of the SCOTROC trial: a phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage Ic-IV epithelial ovarian cancer (EOC) [abstract]. Proc Am Soc Clin Oncol 20:202a, 2001. Abstract 804.
12. Vasey PA; on behalf of the Scottish Gynaecological Cancer Trials Group: Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC) [abstract]. Proc Am Soc Clin Oncol 21:202a, 2002. Abstract 804.
13. The ICON and AGO collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106, 2003.
14. Markman M: Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf 2:141-146, 2003.
15. Fennelly D, Aghajanian C, Shapiro F, et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192, 1997.
16. Markman M, Hall J, Spitz D, et al: Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20:2365-2369, 2002.
17. Sehouli J, Stengel D, Elling D, et al: First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: A phase I study. Gynecol Oncol 85:321-326, 2002.
18. Havrilesky LJ, Alvarez AA, Sayer RA, et al: Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 88:51-57, 2003.
19. Vasey PA, Kaye SB, Morrison R, et al: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin Cancer Res 5:83-94, 1999.
20. Li C, Newman RA, Wu QP, et al: Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol 46:416-422, 2000.
21. Baker B, Bellamy G, Nudelman E, et al: Biodistribution of poly-L-glutamic acid-paclitaxel (CT-2103), and paclitaxel in C57BL/6 mice bearing subcutaneous B16 melanomas [abstract]. Proc Amer Assoc Cancer Res 42, 2001. Abstract.
22. Shaffer S, Baker Lee C, Kumar A, et al: Proteolysis of XYOTAX by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS. Eur J Cancer 38:129, 2002. Abstract 428.
23. Li C, Yu DF, Newman RA, et al: Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 58:2404-2409, 1998.
24. Sabbatini P, Brown J, Peters WA, et al: Phase I/II study of CT-2103 (XYOTAX) in patients with recurrent ovarian cancer [abstract]. Eur J Cancer 38:130, 2002. Abstract 430.
25. Norton MS, Neubauer M, Harper H, et al: Phase 2 study of first line chemotherapy using XYOTAX™ (CT-2103) in patients with non-small-cell lung cancer who are > 70 years of age or performance status (PS)=2 [abstract]. Presented at the 2003 American Society of Clinical Oncology Annual Meeting; Chicago, Ill. Abstract 2626.
26. Shipley D, Greco A, Jones S, et al: Phase 1 study of CT-2103 in patients with non-small cell lung cancer [abstract]. Presented at the 2003 American Society of Clinical Oncology Annual Meeting; Chicago, Ill. Abstract 2833.
27. Robson L, Verrill M, Lind MJ, et al: A phase 2 study of XYOTAX™ (CT-2103), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks in patients with advanced breast cancer [abstract]. Presented at the 2003 American Society of Clinical Oncology Annual Meeting; Chicago, Ill. Abstract 169.
28. Schulz J, Burris H, Redfern C, et al: Phase 2 study of XYOTAX™ (CT-2103) in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen [abstract]. Presented at the 2003 American Society of Clinical Oncology Annual Meeting; Chicago, Ill. Abstract 1137.
29. Verrill MW, Boddy AV, Todd R, et al: Phase 1 pharmacokinetic study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors [abstract]. Presented at the 2003 American Society of Clinical Oncology Annual Meeting; Chicago, Ill. Abstract 533.
30. Kudelka AP, Skubitz K, Kavanagh J, et al: Phase I study of XYOTAX™ (CT-2103) and cisplatin in patients with solid tumors: preliminary data [abstract]. Presented at the 2003 American Society of Clinical Oncology Annual Meeting; Chicago, Ill. Abstract 1841.
31. Nemunaitis J, Bolton M: Phase I study of CT-2103/carboplatin in patients with solid tumors. Eur J Cancer Supplement 1(5):S171, 2003.
32. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989.
33. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994.
34. Markman M, Liu PY, Wilczynski S, et al: Phase 3 randomized trial of 12 versus 3 months of single agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003.